Warning Letter — Almon Healthcare Private Limited
The FDA's Center for Drug Evaluation and Research issued a Warning Letter to Almon Healthcare Private Limited following an agency review or inspection.
This affects Almon Healthcare Private Limited, specifically their drug manufacturing operations and associated quality and regulatory departments.
A Warning Letter from CDER indicates significant deviations from Current Good Manufacturing Practice (CGMP) or other regulatory requirements. This suggests that the firm's quality systems may be insufficient, potentially leading to restricted market access or the requirement for significant remediation efforts to satisfy agency concerns.
Regulatory and QA teams should review site-specific compliance with CGMPS and ensure all manufacturing processes align with CDER-enforced standards. Conduct an immediate audit of current production documentation and facility conditions to identify potential gaps that could trigger similar enforcement actions.
FDA Warning Letter issued to: Almon Healthcare Private Limited. 07/13/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/almon-healthcare-private-limited-729291-07132026
Open in openFDA / FDA.gov